• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AXDX alert in real time by email
    SC 13D/A 1 axdx13da_14.htm



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 14)*

    Accelerate Diagnostics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    00430H201
    (Cusip Number)
     
    Jack W. Schuler
    100 N. Field Drive, Suite 360
    Lake Forest, Illinois 60045
    (224) 880-1210
    (Name, Address, and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    December 3, 2024
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [   ].
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Section 240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.


    (Continued on following pages)
    Page 1 of 6 Pages
    Exhibit Index Found on Page 6


    13D
    CUSIP No. 00430H201
     

    1
    NAMES OF REPORTING PERSONS
     
    Jack W. Schuler
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of: (i) 8,330,613 Shares (as defined in Item 1); (ii) 2022 Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  247,171 Shares; and (iii) 2024 Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 2,716,763 Shares.  Due to exercise limitations set forth in the 2022 Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons do not have the right to exercise any portion of the 2022 Warrants.  Accordingly, as of the date of this filing the aggregate Shares, 2022 Warrants and 2024 Warrants held by the reporting persons represent beneficial ownership of 39.8% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    PF
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    11,047,376 1
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    11,047,376 1
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    11,047,376 1
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    39.8% 2
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Excludes 247,171 Shares for which 2022 Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

    2 The percentages set forth herein are calculated based on 25,043,822 Shares outstanding as of November 5, 2024, as reported by the Issuer in its Form 10-Q filed with the SEC on November 7, 2024.

    Page 2 of 6 Pages

    13D
    CUSIP No. 00430H201
     

    1
    NAMES OF REPORTING PERSONS
     
    Jack W. Schuler Living Trust
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of: (i) 8,330,613 Shares (as defined in Item 1); (ii) 2022 Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  247,171 Shares; and (iii) 2024 Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 2,716,763 Shares.  Due to exercise limitations set forth in the 2022 Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons do not have the right to exercise any portion of the 2022 Warrants.  Accordingly, as of the date of this filing the aggregate Shares, 2022 Warrants and 2024 Warrants held by the reporting persons represent beneficial ownership of 39.8% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Illinois
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    11,027,151 1
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    11,027,151 1
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    11,027,151 1
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    39.7% 2
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    1 Excludes 247,171 Shares for which 2022 Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

    2 The percentages set forth herein are calculated based on 25,043,822 Shares outstanding as of November 5, 2024, as reported by the Issuer in its Form 10-Q filed with the SEC on November 7, 2024.

    Page 3 of 6 Pages


    This Amendment No. 14 to Schedule 13D (this “Amendment”) amends and supplements the Schedule 13D initially filed on May 3, 2012, as amended and supplemented by Amendment No. 1 thereto filed on July 9, 2012, Amendment “No. 1” thereto filed on March 20, 2013, Amendment No. 2 thereto filed on September 3, 2013, Amendment No. 3 thereto filed on March 19, 2014, Amendment No. 4 thereto filed on May 28, 2014, Amendment No. 5 thereto filed on December 29, 2015, Amendment No. 6 thereto filed on February 25, 2016, Amendment No. 7 thereto filed on February 20, 2018, Amendment No. 8 thereto filed April 12, 2018, Amendment No. 9 thereto filed on October 5, 2021, Amendment No. 10 thereto filed on December 3, 2021, Amendment No. 11 thereto filed on June 8, 2023, Amendment No. 12 thereto filed on June 20, 2023 and Amendment No. 13 thereto filed on May 23, 2024 (as so amended and supplemented, the “Prior Schedule 13D” and, as amended and supplemented by this Amendment, this “Schedule 13D”).  Capitalized terms used without definition in this Amendment have the meanings ascribed thereto in the Prior Schedule 13D.

    Preliminary Note

    Capitalized terms used in this Preliminary Note without definition have the meanings ascribed to them elsewhere in this Schedule 13D.

    As of the date hereof: (i) the Trust holds 8,310,388 Shares; (ii) Mr. Schuler holds 20,225 Shares; (iii) the Trust holds Common Stock Warrants (the “2022 Warrants”) issued on August 15, 2022 and expiring on August 15, 2029, which are currently exercisable (subject to the Beneficial Ownership Limitation) for a total of up to 247,171 Shares; (iv) the Trust holds Common Stock Warrants (the “January 2024 Warrants”) issued on January 23, 2024 and expiring five years from the date of issuance, which are currently exercisable for a total of up to 1,156,069 Shares; and (v) the Trust holds Common Stock Warrants (the “May 2024 Warrants” and together with the January 2024 Warrants, the “2024 Warrants”) issued on May 20, 2024 and expiring five years from the date of issuance, which are currently exercisable for a total of up to 1,560,694 Shares.

     The terms of the 2022 Warrants provide that the 2022 Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the Shares then issued and outstanding (the “Beneficial Ownership Limitation”).  As of the date hereof, the Beneficial Ownership Limitation does not permit the Trust to exercise any portion of the 2022 Warrants.  In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the 2022 Warrants held by the Trust are not exercisable due to the Beneficial Ownership Limitation.

    Item 5. Interest in Securities of the Issuer

    This Amendment hereby amends and restates Item 5 of the Prior Schedule 13D in its entirety as follows:

    “Mr. Schuler

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for Mr. Schuler is incorporated herein by reference.  The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 25,043,822 Shares outstanding as of November 5, 2024, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2024.

    (c)
    None.
       
    (d)
    Mr. Schuler has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by him.  The Trust has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants.  Mr. Schuler is the sole trustee of the Trust.
     
    (e)
    Not applicable.

    The Trust

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the Trust is incorporated herein by reference.
     
    (c)
    On December 3, 2024, the Trust sold 200,000 Shares, for a sale price of $1.57 per Share, in a private transaction.  Other than the foregoing, the Reporting Persons did not effect any transactions in the Shares during the 60 days prior to the date hereof.
       
    (d)
    The Trust has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants.  Mr. Schuler is the sole trustee of the Trust.
     
    (e)
    Not applicable.

    As of the date hereof, Mr. Schuler may be deemed to beneficially own, in the aggregate, 11,047,376 Shares, representing 39.8% of the Shares outstanding.  This amount consists of: (i) 20,225 Shares held by Mr. Schuler; (ii) 8,310,388 Shares held by the Trust; and (iii) 2,716,763 Shares for which 2024 Warrants currently are exercisable.  This amount excludes 247,171 Shares for which 2022 Warrants are not currently exercisable due to the Beneficial Ownership Limitation.  As sole trustee of the Trust, Mr. Schuler shares with the Trust the power to vote or direct the vote, and the power to dispose or direct the disposition of, the Shares held by the Trust or acquirable by the Trust upon the exercise of 2024 Warrants.”

    Page 4 of 6 Pages



    SIGNATURES
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
    Dated:  December 5, 2024
     
    /s/ Jack W. Schuler
     
    Jack W. Schuler
       
     
    Jack W. Schuler Living Trust
     
     
    /s/ Jack W. Schuler
     
    By Jack W. Schuler, Sole Trustee
       
    Page 5 of 6 Pages

    EXHIBIT INDEX

    1.
    Joint Acquisition Statement Pursuant to Section 240.13d-1(k), dated June 8, 2023***
    2.
    Standby Purchase Agreement, dated March 10, 2014, by and among Jack W. Schuler as trustee of the Jack W. Schuler Living Trust, the Schuler Family Foundation and Accelerate Diagnostics, Inc.*
    3.
    Form of 2.50% Convertible Senior Note due 2023**
    4.
    Exchange Agreement, dated as of August 15, 2022***
    5.
    2022 Common Stock Warrant, dated as of August 15, 2022***
    6.
    Secured Promissory Note, dated as of August 15, 2022***
    7.
    Consent and Amendment No. 1 to Secured Promissory Note, dated June 9, 2023****
    8.
    Amendment No. 1 to Securities Purchase Agreement, dated June 9, 2023****
    9.
    Securities Purchase Agreement, dated as of June 9, 2023****
    10.
    Subscription Agreement, dated as of January 19, 2024*****
    11.
    Form of January 2024 Common Stock Warrant*****
    12.
    Form of May 2024 Common Stock Warrant*****
       

    * Filed as an Exhibit to the Schedule 13D filed on March 19, 2014

    ** Filed as an Exhibit to the Schedule 13D filed on April 12, 2018

    ***Filed as an Exhibit to the Schedule 13D filed on June 8, 2023

    ****Filed as an Exhibit to the Schedule 13D filed on June 20, 2024

    *****Filed as an Exhibit to the Schedule 13D filed on May 23, 2024

    Page 6 of 6 Pages
    Get the next $AXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXDX

    DatePrice TargetRatingAnalyst
    3/9/2022$5.00Buy → Hold
    Craig-Hallum
    More analyst ratings

    $AXDX
    Financials

    Live finance-specific insights

    See more
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

      TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial for our Accelerate WAVE™ system and the Gram-Negative assay while also

      1/10/25 4:05:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AXDX
    Leadership Updates

    Live Leadership Updates

    See more

    $AXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Accelerate Diagnostics downgraded by Craig-Hallum with a new price target

      Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00

      3/9/22 8:31:56 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement

      TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023. Reichling, who has been with the company since 2012, played a vital role in Accelerate Diagnostics' growth and success over the years. Dur

      3/14/23 8:33:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

      TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important role as Chairman. Hany brings a wealth of leadership and strategic vision, focused on diagnostics and infectious disease testing, which is vital as we grow our

      3/8/23 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Shalhoub Paul Vincent

      3 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      5/1/25 6:40:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:34:08 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Technology Officer Mertz Larry Michael converted options into 4,298 shares and sold $990 worth of shares (1,523 units at $0.65), increasing direct ownership by 3% to 84,803 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:32:39 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    SEC Filings

    See more
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/28/25 4:10:50 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.

      NT 10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/16/25 5:27:55 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/12/25 4:16:21 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

      TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell its assets through a court supervised sale process. Accelerate has filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without material disruption to their ordinary course o

      5/8/25 9:00:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      12/5/24 5:13:13 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Accelerate Diagnostics Inc.

      SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)

      11/14/24 3:24:23 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      8/12/24 5:01:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      12/3/24 8:48:49 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Strobeck Matthew bought 100,000 shares (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:12:05 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Francesconi Louise bought 13,333 shares, increasing direct ownership by 176% to 20,927 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:11:07 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials